Etravirine (TMC-125)

Etravirine (TMC-125)

What is the most important information I should know about etravirine?
• Etravirine is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Tibotec, a biotechnology company in Belgium. The U.S. Food and Drug Administration is now reviewing the safety and effectiveness of etravirine (the company filed a new drug application [NDA] with the agency in July 2007).

Pooled 24-week Data from DUET-1 and DUET-2 Show Etravirine (TMC 125) Is Active Against NNRTI-Resistant HIV - 10/02/07

Lack of Clinically Relevant Drug Interactions Between Ritonavir-boosted Elvitegravir and Experimental NNRTI Etravirine (TMC125) - 9/26/07

Efficacy and Safety of Etravirine (TMC125) in Treatment-experienced HIV Patients: 24-week Results from the DUET-1 and DUET-2 Trials 8/03/07

Notes on the FDA-approved NNRTIs Efavirenz and Nevirapine and a Summary Review of the Experimental NNRTI Etravirine (TMC125) 1/12/07

[PL5.2] TMC125 in combination with other medications: summary of drug-drug interaction studies 11/27/06

[PL5.6] Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227 11/27/06

[P146] No frequent reporting of neurological or psychiatric events during TMC125 treatment 11/27/06

[P277] No effect of TMC125 on the pharmacokinetics of oral contraceptives 11/27/06

[P278] Pharmacokinetics of TMC125, with atazanavir (ATV) and atazanavir/ritonavir (ATV/r) 11/27/06

Two Expanded Access Programs Now Available to Provide Free Access to the Experimental HIV Medications MK-0518 and TMC125 - 9/19/06

48-week Data on TMC 125, a Next Generation Experimental NNRTI from Tibotec Pharmaceuticals - 8/18/06

Combination of Boosted Tipranavir and Experimental PI TMC 125 Is Not Recommended - 2/28/06

Encouraging Data at 13th CROI on Novel New HIV Protease Inhibitor TMC 114 and Unique Non Nucleoside TMC 125 - 2/21/06

FDA-Approved Treatments
for HIV/AIDS

Experimental Treatments
for HIV/AIDS